Hepion Pharmaceuticals, Inc. (HEPA) Fair Value 2026

HEPA · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

3.6 /10

32 fundamental signals · 2 models active

Value Trap Risk

WARN (56/100)

Quick Summary — As of 2026-08-27, Hepion Pharmaceuticals, Inc. (HEPA) trades at $0.05, versus a $0.07 median fair value across its 2 active models — 22.8% above the current price. QOC: 3.6/10. Value Trap Risk: 56/100 (WARN). 2/13 models active.

Key Facts

Ticker
HEPA
Price
$0.05
Quality Score
3.6/10
Value Trap Risk
56/100
Models Active
2/13
Last Updated
Strength: ML-RIV suggests +130.1% upside with 55% confidence
Risk: Value Trap score of 56 suggests caution despite apparent undervaluation

Is Hepion Pharmaceuticals, Inc. (HEPA) Undervalued or Overvalued in 2026?

According to CirclFi’s 2-model valuation engine, Hepion Pharmaceuticals, Inc. (HEPA) appears undervalued as of : the median of 2 independent fair value estimates is $0.07, 22.8% above the current price of $0.05. Estimates range from $0.01 to $0.12. HEPA scores 3.6/10 on fundamental quality and 56/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. HEPA’s +22.8% gap is narrower than that market norm, and the Biotechnology sector median is -64.8%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Hepion Pharmaceuticals, Inc. Stock in 2026? →

What Fair Value Does Each Model Give HEPA?

2 Intrinsic Value Models vs. Current Price ($0.05)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $0.12 +130.1%
Option-Based · Medium Conviction
 $0.01 -84.4%

All Models Active

All 2 models are displayed above.

What Is Hepion Pharmaceuticals, Inc. (HEPA) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Hepion Pharmaceuticals, Inc.'s intrinsic value is estimated at $0.07, presenting a divided outlook at the current price of $0.05. With a median implied return of +22.8% across a split 1–1 (bull–bear) consensus, the model spread of +214.5% underscores analytical uncertainty. Notably, ML-RIV sees the most upside at +130.1% (fair value: $0.12), while PWERM is the most conservative at -84.4% ($0.01). The spread between these extremes — +214.5% — reveals how different analytical frameworks can reach starkly different conclusions.

What Do the Models Say About HEPA?

2 of 13 models are currently active for HEPA. Of these, 1 model suggests upside while 1 model suggests overvaluation. Taken together, their median fair value for HEPA is $0.07 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does HEPA Rank in Biotechnology?

Among 620 Biotechnology stocks, HEPA ranks #561 by Quality of Company score. CirclFi's QOC score of 3.6/10 evaluates 32 fundamental signals. A score of 3.6 signals below-average fundamentals.

See all Most Undervalued Biotechnology Stocks →

The Biotechnology sector introduces analytical considerations specific to life sciences company businesses. For Hepion Pharmaceuticals, Inc., metrics like market exclusivity window provide important context that general-purpose valuation models may underweight.

Is HEPA a Value Trap?

CirclFi's Value Trap algorithm assigns HEPA a score of 56/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

2 of 13 models are active for Hepion Pharmaceuticals, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Hepion Pharmaceuticals, Inc. scores 3.6 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

The gap between the most bullish and bearish model spans +214.5% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every HEPA valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across HEPA's 2 active models, average confidence is 43%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Hepion Pharmaceuticals, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

ALZNAlzamend Neuro, Inc.QOC 3.7ODTXOdyssey Therapeutics, Inc.QOC 3.6RNAAtrium Therapeutics, Inc.QOC 3.7AGMBAgomAb Therapeutics NVQOC 3.6KALAKALA BIO, Inc.QOC 3.7CNBXCNBX Pharmaceuticals Inc.QOC 3.6IMCRImmunocore Holdings plcQOC 6.5PLURPluri Inc.QOC 5.3SYBXSynlogic, Inc.QOC 4.7EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: ALZN · ODTX · RNA · AGMB · KALA · CNBX · IMCR · PLUR · SYBX · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to HEPA?

7 companies across all industries closest to HEPA’s Quality of Company score of 3.6/10.

GCTKGlucoTrack, Inc.QOC 3.6SSMRSunshine Silver Mining & Refining CompanyQOC 3.6AVATAvalanche Treasury CorporationQOC 3.6BENFBeneficientQOC 3.6EEGIEline Entertainment Group, Inc.QOC 3.6FRMIFermi Inc.QOC 3.6NVDANVIDIA CorporationQOC 10.0

Read investment analysis: GCTK · SSMR · AVAT · BENF · EEGI · FRMI · NVDA

Where Does HEPA Sit in CirclFi's Biotechnology Rankings?

HEPA is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Hepion Pharmaceuticals, Inc.’s Valuation?

What is Hepion Pharmaceuticals, Inc.'s intrinsic value in 2026?

CirclFi puts Hepion Pharmaceuticals, Inc. (HEPA)'s intrinsic value at $0.07 — the median of 2 independent model estimates as of 2026-08-27, ranging from $0.01 to $0.12. The Quality of Company score is 3.6/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is HEPA overvalued or undervalued right now?

At $0.05, 1 of 2 active models suggest HEPA may be undervalued, while 1 indicate potential overvaluation. The median of all 2 fair value estimates is $0.07, 22.8% above the current price of $0.05 — a consensus view that HEPA is undervalued. The assessment depends on which methodology best fits Hepion Pharmaceuticals, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 3.6 mean for HEPA?

Hepion Pharmaceuticals, Inc.'s QOC of 3.6/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on HEPA?

CirclFi analyzes HEPA with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 2 of 13 are active for this stock. Read the full methodology →

Is HEPA a value trap in 2026?

Hepion Pharmaceuticals, Inc.'s Value Trap score is 56/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 2-model valuation engine, Hepion Pharmaceuticals, Inc. (HEPA) has a median fair value of $0.07 — 22.8% above the current price of $0.05 — as of 2026-08-27.” Source: circlfi.com/stock/HEPA/ · Methodology
Primary sources for this HEPA valuation
  • Financial statements: Hepion Pharmaceuticals, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001583771) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for HEPA as of ; valuations recomputed .